Search
Menu
Home
HTB
2017
November
24
HTB
24 November 2017
Contents
Antiretrovirals
Coformulated dolutegravir plus rilpivirine approved in US (Juluca)
Darunavir-based single pill FDC approved in EU (Symtuza)
HTB RSS
Early access
Vertical transmission rate below 0.3% among women living with HIV in the UK
31 October 2022
HIV Glasgow Congress 2022
31 October 2022
Metabolic complications of newer HIV drugs in older people
30 October 2022
Cabotegravir-LA submitted to EMA for use as PrEP in Europe
28 October 2022
All early access reports
Current issues
October 2022
September 2022
August 2022
Back issues
Special report
Monkeypox into Autumn: still no emergency funding, vaccine efficacy and UK declines further vaccines
3 October 2022
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage
